Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Alnylam Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of RNA interference therapeutics. They currently have an approved product, ONPATTRO (patisaran), and multiple pipeline products. The company currently appears to be a good swing trade. Click to read more about my technical analysis and their siRNA technology


Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)

Agios Pharmaceuticals, Inc. is a company I see potential value in. From a technical analysis standpoint, it appears a reversal was confirmed in 2019 and has trended positively. It appears to have met a resistance around $66 and currently found a support near $56. If the support is confirmed, Agios may continue following their positive trend. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, TIBSOVO® (ivosidenib) and IDHIFA® (enasidenib), and three other products in clinical development.